Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)

Clinical trial NCT07287202 · RECRUITING

Trial details

NCT number: NCT07287202
Sponsor: Sovargen
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Focal Cortical Dysplasia Tuberous Sclerosis Complex (TSC)Hemimegalencephaly

Start date: 2026-07-14
Primary completion: 2027-02-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.